
News|Articles|March 1, 2007
First-time generic approvals
First-time generic approvals
Advertisement
First-time generic approvals
Valacyclovir tablets, 500 mg (base) and 1 g (base) (equiv to Valtrex caplets)
RANBAXY
Albuterol sulfate extended-release tablets, 4 mg (base) and 8 mg (base) (equiv to VoSpire ER tablets)
MYLAN
Fentanyl-12 transdermal system, 12.5 mcg/h (equiv to Duragesic-12)
MYLAN
Dexmethylphenidate tablets, 2.5, 5, and 10 mg (equiv to Focalin tablets)
TEVA
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
HS patients on biosimilar adalimumab lose response faster than those on the original drug
2
CMS negotiates a 70% discount for Ozempic and Wegovy
3
Global MS analysis links disability burden to rising economic strain
4
New drug class shows promise for geographic atrophy
5






















































